Navigation Links
National Pharmaceutical Council Studies New Formulary Decision-Making Tool
Date:8/19/2013

WASHINGTON, Aug. 19, 2013 /PRNewswire-USNewswire/ -- A National Pharmaceutical Council (NPC) study published in the peer-reviewed journal Pharmacy and Therapeutics details new work in developing, testing and piloting a more structured approach to formulary decision-making.

The study, "Transparency in Evidence Evaluation and Formulary Decision-Making," discusses efforts to increase the clarity, consistency, and transparency of how evidence is applied by payers during the formulary decision-making process. During the project, the new approach was evaluated in a pharmacy and therapeutics setting.

"Right now, there is a bit of a 'black box' around the formulary decision-making process," said Robert Dubois, MD, Ph.D., NPC's chief science officer and an author of the study. "As a result, decisions about treatment access are often unpredictable to patients, providers and biopharmaceutical manufacturers. We sought to identify ways to clarify the process."

The project, conducted with Cerner Research and other research experts, and sponsored in part by Pfizer Inc, was completed in three phases. First, an expert panel was leveraged to create an evidence assessment tool based on the core elements of formulary decision-making: safety, efficacy, cost and certainty of evidence. Next, the evidence assessment tool was validated by surveying a larger group of medical and pharmacy directors. Finally, the tool was piloted in a real-world pharmacy and therapeutics (P&T) environment.

Survey responses from the validation process with medical and pharmacy directors indicated that the tool could increase clarity, consistency and transparency in formulary decision-making. In the hypothetical scenarios tested using the tool, increased formulary access was associated with greater efficacy, more evidence certainty, fewer safety concerns and lower costs.

However, the tool did not hold up during real-world pilot testing. Participants in the pilot-testing portion of the project indicated that the tool did not capture the dynamic and complex variables involved in the formulary decision-making process, and therefore would not be suitable for more sophisticated organizations.

"The results of this study show that we need to pursue other approaches for promoting a process that ensures all stakeholders know the 'ingredients' that go into decision-making and how evidence is applied," said Jennifer Graff, PharmD, NPC director of comparative effectiveness research and a study author. "While our results show that this may not be the right approach for consistently translating evidence into decision-making, we have made progress in terms of supporting better approaches to evaluating the evidence. For groups with less rigorous or structured processes for conducting reviews, this may be a good starting point."

In addition to its previous research on how payers assess evidence, NPC is continuing to explore ways to enhance the processes used to evaluate evidence. In particular, NPC is working with the Academy of Managed Care Pharmacy (AMCP) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) on a joint project called the CER Collaborative Initiative to provide greater uniformity and transparency in the evaluation and use of evidence for coverage and health care decision-making. The CER Collaborative is developing a user-friendly toolkit and training materials to help increase decision-makers' awareness, understanding, and confidence in their abilities to critically appraise individual studies and synthesize the evidence from a variety of study methods to guide formulary decisions.

NPC also will host a webinar about the research, along with a discussion about how payers are evaluating evidence, on September 10, 2013 from 1 p.m. – 2 p.m. ET. Registration is available online at http://www.npcnow.org/event/webinar-transparency-evidence-evaluation-and-formulary-decision-making.

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.


'/>"/>
SOURCE National Pharmaceutical Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
6. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
7. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
8. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
9. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
10. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
11. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DUBLIN , Mar 29, 2017 Research ... Global Market - Forecast to 2023" report to their offering. ... The ablation ... CAGR to reach $20,995.5 million by 2023. Ablation ... wide range of purposes, from cancerous or diseased tissue removal, to ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education Partners’ ... the field must first improve teacher preparation program design. It then asserts that ... that decades of input- and outcome-based research has failed to improve teacher education. ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s ... technology to directly address the resolution to globally reduce the harmful use of ... compound of FDA and TTB approved ingredients that when infused into alcohol, renders ...
(Date:3/28/2017)... WASHINGTON, DC (PRWEB) , ... March 28, 2017 ... ... call on elected representatives in state legislatures and Congress to protect parental rights ... the public health and safety in America. , The demonstration coincides with a ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of all holidays (IBT World Travel Trends Report). As travelers visit both urban ... range in temperatures, and prolonged sun exposure. In response, the outdoor industry has ...
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
Breaking Medicine News(10 mins):